

Fig. 2. Effect of IVT vehicle (○○○○) or calcitonin (8 U/kg) injection (.....) on conscious rabbit brain electrogenesis at various times after administration (Mean values and S.D. of 8 animals). The integrated EEG recorded from NC is taken as representative of the tracings from all the areas considered.

data would suggest that the effect might be dose-related, but they are not included in Figure 1 because only a few animals have been so far tested.

The calcium levels after IVT calcitonin showed a progressive decrease from the basal mean value of  $11.8 \pm 1.1$  mg/100 ml to  $10.6 \pm 1.3$ ,  $7.7 \pm 0.5$ ,  $7.5 \pm 0.2$  mg/100 ml at 30, 60 and 90 min respectively. This fact indicates a leaking of the polypeptide from the brain to the peripheral blood. The significance of changes of calcium ions in analgesia is highlighted also by the reported increase of the analgesic action of morphine and other opiates consequent to a decalcifying agent administration<sup>6</sup>. On the other hand, an involvement of changes of calcium within the neurons induced by calcitonin seems a worthwhile hypothesis, since an influence of the polypeptide on intracellular calcium distribution is suggested as the mechanism through which calcitonin carries out its hormonal action on target cells<sup>7</sup>.

As to the results of the EEG studies (Figure 2), we have seen an initial decrease in the average electrogenesis recorded from all the different brain areas which persists about 10 min after the IVT administration both of the vehicle and of calcitonin solution. Then, only in calcitonin-treated rabbits, a phase of progressive increase of EEG voltage follows which reaches its peak approximately in coincidence with the maximal antinociceptive effect (Figures 1 and 2). The integrated voltage values corresponding to the area of the nucleus caudatus plotted in Figure 1 are representative also of other brain areas recorded.

Considering that all the structures from which EEG tracings have been recorded showed similar changes, it is impossible to indicate a specific centre for the action of

calcitonin. The parallel increase of all electrical brain potentials and of the thresholds to painful stimuli favours the possibility of a diffuse involvement of neurons' populations by calcitonin, but does not exclude that other areas, not yet investigated, may be more specifically responsive.

Under IVT administration of calcitonin, the conscious rabbits were at first behaviourally excited with signs of hypertonia particularly evident in the neck muscles. Subsequently they showed periodically restlessness with spontaneous running movements.

In conclusion, calcitonin injected into the brain ventricle elicits clear-cut effects including analgesia, the mechanism of which remains largely unknown but deserves further investigation.

*Riassunto.* La iniezione di calcitonina nei ventricoli cerebrali di conigli non anestetizzati induce analgesia e variazioni elettroencefalografiche con prevalente innalzamento dei potenziali elettrici di diverse aree cerebrali considerate.

A. PECILE, S. FERRI, P. C. BRAGA and V. R. OLGATI

3rd Chair of Pharmacology, Faculty of Medicine of the University, Via Vanvitelli 32, I-20129 Milano (Italy), and Chair of Applied Pharmacology, Faculty of Sciences, Milano (Italy), 1 August 1974.

<sup>6</sup> T. KAKUNAGA, H. KANETO and K. HANO, *J. Pharmac. exp. Ther.* 153, 134 (1966).

<sup>7</sup> A. B. BORLE, in *Les hormones et le calcium* (Ed. H. P. KLOTZ; Expansion Scientifique Francaise, Paris 1971), p. 5.

### Potential of the Effect of Histamine by PGE<sub>2</sub> in the Isolated Perfused Rabbit Kidney and Guinea-Pig Lung

We recently indicated that histamine produces a vasoconstrictor effect on the isolated perfused rabbit kidney and guinea-pig lung acting on histamine H<sub>1</sub>-receptors. The vasoconstrictor action of the amine was converted into a vasodilator one by histamine H<sub>1</sub>-receptor blockers. The vasodilator action of histamine is due to the stimulation of H<sub>2</sub>-receptor since the competitive inhibitors of these receptors (burimamide and meti-

amide) can significantly inhibit this effect<sup>1,2</sup>. The H<sub>2</sub>-receptor blockers added to the perfusion medium cause a potentiation on the vasoconstrictor effect of the amine because of the elimination of masked vasodilator action

<sup>1</sup> R. K. TÜRKER, *Pharmacology* 9, 306 (1973).

<sup>2</sup> T. A. BÖKESÖY and R. K. TÜRKER, *Archs int. Pharmacodyn. Thé.* 209, 144 (1974).

of histamine<sup>1,2</sup>. In the present study we observed similar potentiation of the effect of histamine by prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) in the same isolated perfused organs.

**Material and method.** The experiments were carried out in the isolated perfused rabbit kidney and guinea-pig lung from adult animals of both sexes. After sodium pentobarbital anesthesia (30 mg/kg i.v.), the animals were injected with sodium heparin (500 U/kg i.v.), then the kidney was isolated and perfused as described previously<sup>3</sup>. The lungs were isolated according to the method of BAKHLE et al.<sup>4</sup>. Both organs were perfused with oxygenated (95% O<sub>2</sub> and 5% CO<sub>2</sub> mixture) and warmed (37°C) Krebs' solution. The flow rate was 17 ml/min for the kidney and 10 ml/min for the lung. It was kept constant throughout the experiment. Perfusion

pressure was measured by a pressure transducer (Statham p 23 Dc) and recorded on a Beckman type RB Dynograph. Urine drops were recorded simultaneously by a magnetic tipper from the cannulated ureter. The results were statistically evaluated using Student's *t*-test.

**Results.** Histamine caused a dose-dependent increase in both perfusion pressure and urine volume when given through the renal artery as single injections. Figure 1 shows the dose-response curves of histamine before and after addition of PGE<sub>2</sub> into the perfusion fluid. A parallel shift to the left was observed in the curves for each parameter after PGE<sub>2</sub>. The estimated ED<sub>50</sub> value of histamine was found to be about 4 µg/ml in control experiments and about 1 µg/ml in presence of PGE<sub>2</sub>. Addition of metiamide (1 µg/ml) into the perfusion fluid




Fig. 1. The dose-response curve of histamine in the isolated perfused rabbit kidney. Each point represents the mean value of 15 experiments. Vertical bars shows S.E.M.




Fig. 2. The dose-response curve of histamine in the isolated perfused guinea-pig lung. Each point represents the mean value of 15 experiments. Vertical bars indicates S.E.M.

did not cause further potentiation. Similar results were obtained in the isolated perfused guinea-pig lung as summarized in Figure 2. PGE<sub>2</sub> did not cause a potentiation of the effect of noradrenaline, angiotensin and serotonin.

Addition of theophylline ( $1 \times 10^{-5}$  M) into the fluid perfusing kidney and lung caused a significant decrease in the pressor response induced by histamine without changing the effect of noradrenaline, angiotensin and 5-HT. Theophylline also antagonized the potentiation of the pressor effect of histamine induced by PGE<sub>2</sub>.

**Discussion.** The results of the present study show that PGE<sub>2</sub> specifically potentiates the effect of histamine but not that of noradrenaline, angiotensin II and 5-HT in the isolated perfused rabbit kidney and guinea-pig lung. We previously observed that histamine has a vasodilator effect through the stimulation of H<sub>2</sub>-receptors in both organs<sup>1,2</sup>. In normal Krebs-perfused organs, this effect is masked by the pressor action of histamine which occurs by the stimulation of H<sub>1</sub>-receptors. The blockade of H<sub>2</sub>-receptors by burimamide can cause a potentiation of the pressor because of the elimination of masked action of the amine in opposite direction<sup>1</sup>. In the present study

<sup>3</sup> Ü. N. GÜNDOĞAN and R. K. TÜRKER, *Pharmacology* 11, 278 (1974).

<sup>4</sup> Y. S. BAKHLE, A. M. REYNARD and J. R. VANE, *Nature, Lond.* 222, 956 (1969).

another  $H_2$ -receptor blocker, metiamide<sup>5</sup>, as well as  $PGE_2$  can induce equal potentiation in both organs. This suggests a common mechanism for both compounds. The first explanation is that  $PGE_2$  may have a blocking effect on  $H_2$ -receptors. This seems unlikely since  $PGE_2$  does not inhibit the relaxation (unpublished observation) induced by histamine in the cat tracheal muscle, which has been shown to be mediated by  $H_2$ -receptors<sup>6</sup>.

It has previously been shown that histamine may stimulate the gastric acid secretion<sup>7</sup> and heart muscle<sup>8</sup> simultaneously with an increase of cellular cyclic AMP level. Both effects have been found to be blocked by burimamide. It seems likely that the stimulation of  $H_2$ -receptors in both perfused organs can produce the

vasodilator effect by the increase of second messenger system, cyclic AMP. This speculation has been based upon findings obtained with theophylline, which has been described as a potent inhibitor of phosphodiesterase<sup>9</sup>. Addition of theophylline to the perfusion medium causes an inhibition of the pressor effect of histamine in both organs. This effect is probably due to the accumulation of cyclic AMP which represents the stimulation of  $H_2$ -receptors. Since theophylline antagonizes the potentiating action of  $PGE_2$  on histamine responses in both organs, it is highly possible that  $PGE_2$  and theophylline influence phosphodiesterase in opposite directions. Another possibility should be taken into consideration that  $PGE_2$  may inhibit adenyl cyclase activity and consequently cause an inhibition of cyclic AMP in the cellular level. This point is still under investigation.

<sup>5</sup> J. W. BLACK, W. A. M. DUNCAN, J. C. EMMETT, C. R. GANELLIN, T. HESSELBO, M. E. PARSONS and J. H. WYLLIE, *Agents Actions* 3, 133 (1973).

<sup>6</sup> P. EYRE, *Br. J. Pharmac.* 48, 321 (1973).

<sup>7</sup> H. O. KARPPANEN and E. WESTERMANN, *Naunyn-Schmiedeberg's Arch. Pharma.* 279, 83 (1973).

<sup>8</sup> G. PÖCH, W. R. KUKOVETZ and N. SCHAZ, *Naunyn-Schmiedeberg's Arch. Pharmak.* 280, 223 (1973).

<sup>9</sup> U. SCHWARBE and R. EBERT, *Naunyn-Schmiedeberg's Arch. Pharmak.* 274, 287 (1973).

<sup>10</sup> We would like to thank to Dr. W. A. M. DUNCAN, Vice-President, Research-Europe, Smith-Kline & French Laboratories, Welwyn Garden City, Herts, England, for his generous gift of metiamide and to Dr. J. E. PRIKE, Department of Experimental Chemistry Research, The Upjohn Co., Kalamazoo, Mich., USA, for  $PGE_2$ .

*Zusammenfassung.*  $PGE_2$  verstärkt an isoliert perfundierten Kaninchennieren und Meerschweinchenlungen die Wirkung von Histamin auf den Perfusionsdruck. Gleiches wurde auch mit Metiamid, einem  $H_2$ -Rezeptorblocker, beobachtet. Anhand dieser Befunde wird die mögliche Rolle von c-AMP bei dieser Verstärkerwirkung diskutiert.

Z. S. ERCAN and R. K. TÜRKER<sup>10</sup>

*Department of Pharmacology, Faculty of Medicine, University of Ankara, Ankara (Turkey), 30 October 1974.*

## The Metabolism of Phenylethylamine and O-Methylated Derivatives by Monoamine Oxidase

Phenylethylamine (PEA) and paramethoxyphenylethylamine (PMPEA) are sympathomimetic agents similar in structure to the catecholamines. Both compounds cross the blood-brain barrier and can cause central effects. PEA induces a strong, amphetamine-like central stimulation<sup>1</sup>, while PMPEA administration results in a short-lasting catatonic state<sup>2</sup>. Similar catatonic responses have also been observed following the administration of 3,4-dimethoxyphenylethylamine (3,4 DMPEA)<sup>3</sup>. Pretreatment with monoamine oxidase (MAO) inhibitors potentiates the depletion of central monoamines by PEA<sup>4</sup> and prolongs the effects of PMPEA on monosynaptic spinal reflexes<sup>5</sup>. Thus it is likely that PEA, and PMPEA, are metabolized *in vivo* by MAO, the enzyme responsible for the intraneuronal inactivation of biogenic amines. In this study we have compared the effects of PEA and PMPEA, as well as those of the dimethoxy derivatives (2,3 and 3,4 DMPEA) on brain MAO activity *in vitro*.

*Methods of procedure.* The metabolism of phenylethylamine and its derivatives was studied indirectly, by measurement of MAO activity *in vitro* in the presence of these agents. A water homogenate of rat brain stem (pons and medulla) was the enzyme source for these *in vitro* studies. MAO was measured by a modification of the micro method of McCAMAN<sup>6</sup>, using C<sup>14</sup> tyramine as substrate. For kinetic analysis, enzyme activities were measured at several substrate concentrations in the presence of varying concentrations of the compound tested. MAO activity was expressed as millimoles of substrate deaminated/g protein/h. Data were plotted by the method of LINEWEAVER-BURK<sup>7</sup> to give values for  $K_m$  and  $V_{max}$ . Competitive inhibitions is observed where  $K_m$ , but not  $V_{max}$ , is changed as compared to controls.

In cases of competitive inhibition, the concentration of the inhibitor necessary to produce half maximal inhibition ( $K_i$ ) was calculated from the slope of the LINEWEAVER-BURK curves. For non-competitive inhibition approximate  $K_i$  values have been calculated.

*Results.* The interactions of PEA and PMPEA with rat brain MAO are described in Figures 1A and 1B, respectively. Although both compounds inhibit brain MAO with tyramine as substrate, the nature of the inhibition differs. PEA is a non-competitive inhibitor (Figure 1A), whereas PMPEA inhibits in a competitive manner (Figure 1B). Qualitatively and quantitatively similar results were obtained with serotonin and dopamine as substrates. The concentration of PMPEA required to give half-maximal inhibition ( $K_i$ ) is 18.0  $\mu M$ . For PEA a series of  $K_i$  values are obtained, in the range of 87–142  $\mu M$ .

<sup>1</sup> J. JONSSON, H. GROBECKER and P. HOLTZ, *Life Sci.* 5, 2235 (1966).

<sup>2</sup> R. ASHKENAZI, B. HABER, J. D. COULTER and W. D. WILLIS JR., *Soc. for Neuroscience, Third Meeting, Abstract 42.8* (1973).

<sup>3</sup> M. L. BROWN, W. J. LANG and S. GERSHON, *Archs. int. Pharmacodyn* 158, 439 (1965).

<sup>4</sup> K. FUXE, H. GROBECKER and J. JONSSON, *Eur. J. Pharmac.* 2, 202 (1967).

<sup>5</sup> W. D. WILLIS JR., R. ASHKENAZI, J. C. WILLIS and B. HABER, *Texas Rep. Biol. Med.* 31, 423 (1973).

<sup>6</sup> R. E. McCAMAN, M. W. McCAMAN, J. M. HUNT and M. S. SMITH, *J. Neurochem.* 12, 15 (1965).

<sup>7</sup> H. LINEWEAVER and D. BURK, *J. Am. chem. Soc.* 56, 658 (1934).